| 摘要 |
Abstract 599901 The present disclosure provides a medicinal aerosol suspension formulation for MDl administration, comprising: a) micronized formoterol fumarate or a pharmaceutically acceptable salt thereof; b) micronized fluticasone propionate or a pharmaceutically acceptable salt thereof; c) a sub-therapeutic quantity of a moisture-scavenger excipient comprising sodium cromolyn; and d) a HFA propellant; wherein (a), (b) and (c) and their respective relative amounts are selected such that they associate to form floccules having a density substantially the same as that of the HFA propellant.
|
